Display Settings:

Format

Send to:

Choose Destination
N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Collaborators (225)

Bampton P, Chung A, Debinski H, Florin T, Hetzel D, Kronborg I, Lawrance I, Leong R, Macrae F, Moore G, Pavli P, Radford-Smith G, Weltman M, Haas T, Reinisch W, Stockenhuber F, Vogel W, De Maeyer M, De Vos M, D'Haens G, Louis E, Muls V, Van Assche G, Petrov P, Aumais G, Axler J, Bitton A, Bourdages R, Bressler B, Cohen A, Fedorak R, Greenberg G, Jones J, Kutcher W, MacIntosh D, Ponich T, Singh R, Steinhart H, Sy R, Douda L, Lukas M, Samek M, Vyhnalek P, Woznica V, Zadorova Z, Andersen V, Rannem T, Staun M, Maelt A, Margus B, Bonaz B, Coffin B, Desreumaux P, Laharie D, Reimund JM, Karaus M, Pace A, Ross M, Schmidt W, Witthoeft T, Zeitz M, Karamanolis D, Mantzaris G, Maris T, Ng C, Gall J, Hunyady B, Szepes A, Toth T, Vincze A, Oddsson E, Jósefsspktali KÖ, Ahuja V, Amarapurkar D, Goenka M, Habeeb MA, Jalihal U, Kalambe B, Koshy A, Kumar R, Prasad V, Reddy N, Sekar T, Shankar R, Tantry V, Ryan B, Avni Y, Ben Horin S, Ardizzone S, Armuzzi A, Corazziari E, Danese S, Fries W, Kohn A, Lisova D, George AM, Hilmi IN, Bhaskaran SK, Soon SY, Engels L, Ponsioen C, Wallace I, Wyeth J, Florholmen J, Jahnsen J, Lygren I, Röseth A, Ciecko-Michalska I, Gonciarz M, Huk J, Jamrozik-Kruk Z, Kondusz-Szklarz M, Paradowski L, Wiechowska-Kozlowska A, Han DS, Hong SP, Kim HJ, Kim JS, Kim KO, Kim YH, Yang SK, Alexeeva O, Bunkova E, Burnevich E, Dolgikh O, Kasherininova I, Khovaeva Y, Lakhin A, Ling KL, Bester F, Coetzer T, Grundling Hde K, Jackson LD, Spies P, Wright JP, Ziady C, Garcia Planella E, Perez Gisbert J, Rogler G, Seibold F, Kao AW, Wu DC, Atug O, Kurdas OO, Hawthorne AB, Lindsay J, Abreu M, Aggarwal A, Bala N, Becker S, Behm B, Braun R, Cohn W, Cross R, Dar S, Dassopoulos T, De Villiers W, Desta T, Dryden G, Duvall A, Farraye F, Fein S, Liu BF, Gatof D, Geenen D, Ginsburg P, Glover S, Gopal V, Hanauer S, Hanson J, Hardi R, Isaacs K, Jain R, Karyotakis N, Korzenik J, Koshy G, Koval G, Lawitz E, Lee S, Loftus E, Luther R, Mahadevan U, Mannon P, Matsuyama R, McIntosh A, Melmed G, Mirkin K, Nichols M, Oubre B, Pandak W, Quadri A, Quallich L, Randall C, Rausher D, Regueiro M, Safdi A, Sands B, Scherl E, Schneier J, Schwartz D, Sedghi S, Shafran I, Siegel C, Stein L, Tatum H, Weinberg D, Winston B, Wolf D, Younes Z, Feagan BG, Colombel JF, Hanauer S, Rutgeerts P, Sandborn WJ, Sands BE, Jewell D, Mahon J, Rothstein R, Snydman D, Massaro J, Clifford D, Berger J, Major E, Provenzale J, Lev M.

Author information

  • 1Robarts Clinical Trials, Robarts Research Institute, and Department of Medicine, University of Western Ontario, London, Canada. bfeagan@robarts.ca

Abstract

BACKGROUND:

Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis.

METHODS:

We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients with active disease. In the trial of induction therapy, 374 patients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intravenously at weeks 0 and 2, and 521 patients (cohort 2) received open-label vedolizumab at weeks 0 and 2, with disease evaluation at week 6. In the trial of maintenance therapy, patients in either cohort who had a response to vedolizumab at week 6 were randomly assigned to continue receiving vedolizumab every 8 or 4 weeks or to switch to placebo for up to 52 weeks. A response was defined as a reduction in the Mayo Clinic score (range, 0 to 12, with higher scores indicating more active disease) of at least 3 points and a decrease of at least 30% from baseline, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1.

RESULTS:

Response rates at week 6 were 47.1% and 25.5% among patients in the vedolizumab group and placebo group, respectively (difference with adjustment for stratification factors, 21.7 percentage points; 95% confidence interval [CI], 11.6 to 31.7; P<0.001). At week 52, 41.8% of patients who continued to receive vedolizumab every 8 weeks and 44.8% of patients who continued to receive vedolizumab every 4 weeks were in clinical remission (Mayo Clinic score ≤2 and no subscore >1), as compared with 15.9% of patients who switched to placebo (adjusted difference, 26.1 percentage points for vedolizumab every 8 weeks vs. placebo [95% CI, 14.9 to 37.2; P<0.001] and 29.1 percentage points for vedolizumab every 4 weeks vs. placebo [95% CI, 17.9 to 40.4; P<0.001]). The frequency of adverse events was similar in the vedolizumab and placebo groups.

CONCLUSIONS:

Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis. (Funded by Millennium Pharmaceuticals; GEMINI 1 ClinicalTrials.gov number, NCT00783718.).

Comment in

PMID:
23964932
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Atypon
    Loading ...
    Write to the Help Desk